PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Cobimetinib

Drugs in development · updated 30 October 2026

Cobimetinib: clinical trials and development status

Other names and codes: Cotellic

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 20 November 2015

As of 30 October 2026 Cobimetinib is in 27 active clinical trials (recruiting or ongoing, phases I–III) for 35 diseases. The most advanced phase is III.

27Active trials
IIIMost advanced phase
35Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Cobimetinib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 35 diseases.

DiseaseMost advanced phaseActive trialsReference trial
NeoplasmIII6NCT03768063
MelanomaII–III5NCT05768178
Non-small-cell lung carcinomaII–III5NCT03178552
Hematologic neoplasmII–III3NCT05722886
Multiple myelomaII–III3NCT05768178
Anaplastic thyroid carcinomaII–III2NCT05768178
Erdheim-Chester diseaseII–III2NCT05768178
Ovarian neoplasmII–III2NCT05768178
Papillary thyroid cancerII–III2NCT05768178
Colorectal neoplasmII–III1NCT05768178
GliomaII–III1NCT05768178
Laryngeal neoplasmII–III1NCT05768178
Lymphoproliferative disordersII–III1NCT05722886
Lung neoplasmII2NCT03600701
Non-Hodgkin lymphomaII2NCT02693535
Adenocarcinoma, FollicularII1NCT06440850
Brain NeoplasmsII1NCT03175432
CarcinomaII1NCT06813079
CholangiocarcinomaII1NCT04941287
Chronic myelomonocytic leukemiaII1NCT04409639
CraniopharyngiomaII1NCT03224767
Gallbladder neoplasmII1NCT04941287
Histiocytic Disorders, MalignantII1NCT04079179
Histiocytic sarcomaII1NCT04079179
Histiocytosis, SinusII1NCT04079179
Inflammatory breast cancerII1NCT03202316
Juvenile xanthogranulomaII1NCT04079179
Langerhans-cell histiocytosisII1NCT04079179
Pancreatic ductal carcinomaII1NCT06813079
Thyroid neoplasmII1NCT03181100

Everything on Cobimetinib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch